4553d589 898d 45f2 A195 D6e6526a446b 00
Gabapentin Capsule
Product Images NDC 0904-6665
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 0904-6665). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
4553d589 898d 45f2 A195 D6e6526a446b 01
This appears to be a medication label for Gabapentin capsules. The NDC number, dosage and usage information, precautions and warnings, and the pharmacist's instruction to dispense a medication guide to each patient are provided. The text also mentions the product's packaging as being intended for institutional use only and reminds the user to keep the medication out of the reach of children.*
4553d589 898d 45f2 A195 D6e6526a446b 02
This text describes a medication named Gabapentin in the form of capsules, which are dispensed by a pharmacist along with a medication guide for each patient. The medication contains 100 capsules per prescription, and the packaging warns against keeping it out of reach of children and pets. Detailed prescribing information, including dosage and precautions, can be found on the product insert. The manufacturer is listed as ZHMAJOR Pharmaceuticals and the medication is only available through prescription.*
Gabapentin-equation (Gabapentin Equation)
This appears to be a formula for a calculation involving weight and serum creatinine levels. It is unclear what the purpose or context of this calculation is without further information.*
Gabapentin-fig1 (Gabapentin Fig1)
This appears to be a chart displaying the mean pain scores during a period of 4 weeks where the dosage of medication was being titrated followed by a 4-week period where the dosage remained fixed. The medication being studied was Gabapentin, with a maximum dose of 3600mg per day, and a placebo was also tested. The baseline pain score is not specified.*
Gabapentin-fig2 (Gabapentin Fig2)
The text describes a chart or table showing the mean pain score for different doses of Gabapentin over a titration period and a fixed dose period, compared to placebo. It includes two columns labeled "Baseline" and "Weeks" and some numerical values, but not enough information is given to fully understand the results or context of the data.*
Gabapentin-fig3 (Gabapentin Fig3)
This appears to be a chart presenting data on a study regarding treatments for controlled postherpetic neuralgia (PHN). The chart displays the percentage of responders (patients with a 2 50% reduction in pain score) at endpoint and includes different treatments such as GBP 3600, PBO, GEBP 1800, and GBP 2400. There are also percentages ranging from 100% to 10%. The chart mentions a study and some statistical significance (p<0.001) but without further context, it is not possible to determine the full implications of this data.*
Gabapentin-fig4 (Gabapentin Fig4)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
